Sector News

Hostile Sanofi puts forth its slate of Medivation directors

May 26, 2016
Life sciences

Sanofi is powering through with its hostile takeover attempt for Medivation–and as it does, even more potential suitors may be weighing an entry into the fray.

Wednesday, the French pharma giant put forth a slate of 8 candidates to replace the California drugmaker’s entire board–a move it had “no choice” but to make, given Medivation’s rejection of Sanofi’s $9.3 billion offer and refusal to come to the bargaining table, CEO Olivier Brandicourt said in a statement.

Sanofi’s board nominees–Michael Campbell, Barbara Deptula, Wendy Lane, Ronald Rolfe, Steven Shulman, Charles Slacik, James Tyree and David Wilson–boast experience in pharma, finance and law, and the way the company sees it, their openness to a potential deal makes them “more open to supporting the best interests of Medivation shareholders.”

Sanofi, eager to add Medivation prostate cancer phenom Xtandi to an oncology portfolio that needs a boost, has been pursuing Medivation for months now, despite getting the cold shoulder. The San Francisco company urged its shareholders Wednesday to reject Sanofi’s attempt at a board overhaul, reiterating its opinion that the Big Pharma’s $52.50-per-share offer “substantially undervalues” it.

Meanwhile, though, other interested parties have begun lining up–and they haven’t all met with the same chilly reception. Earlier this month, Reuters reported that Medivation had opened its books up to wannabe buyers including Pfizer and Amgen–a play Sanofi was none too happy about.

“There have been published reports that you have signed confidentiality agreements with other parties. If that is accurate, we cannot see how you have not done so with us,” Brandicourt wrote in a letter to Medivation’s board.

Unfortunately for Sanofi, the line to talk takeover with Medivation may be getting longer instead of shorter. Biotech heavyweights Celgene and Gilead are now considering making their own bids for the company, Bloomberg reported Wednesday; they join a list of rumored suitors that already includes Pfizer, Amgen, Novartis and AstraZeneca.

By Carly Helfand

Source: Fierce Pharma

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 23, 2021

Thermo Fisher Scientific acquires Novasep’s Henogen for $874.5m

Life sciences

Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash. Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.

January 23, 2021

Lilly and Merus partner to develop T-Cell re-directing antibody therapies

Life sciences

Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.

January 23, 2021

Adagene plans $125M IPO to go after cancer niches targeted by BMS and Pfizer

Life sciences

Chinese cancer biotech Adagene has filed to raise up to $125 million in a Nasdaq IPO. The listing will give Adagene the means to run early-phase clinical trials of antibodies against CD137 and CTLA-4.

Send this to a friend